Oxolamine is a cough suppressant that is available as a generic drug in many jurisdictions. Oxolamine also has anti-inflammatory activity, which causes a reduction in irritation of the nerve receptors of the respiratory tract. Technically, oxolamine is commonly supplied as the citrate salt to improve aqueous solubility for oral formulations such as tablets and syrups. The active substance is a small-molecule amine that reduces cough reflex sensitivity primarily by decreasing local inflammatory mediators and sensory receptor activation in the airways; the citrate form facilitates reliable dosing and bioavailability in clinical preparations. Oxolamine is formulated alone or in combination with expectorants or antihistamines for symptomatic relief of cough associated with upper respiratory inflammation. In pharmaceutical handling it appears as a crystalline powder with typical pharmaceutical-grade purity and requires standard controls for residual solvents, heavy metals and microbial limits.
Typical pharmaceutical specifications for oxolamine reference a high assay and low levels of related substances. A representative specification would state assay not less than 98.0 percent on an anhydrous basis. Related compounds and specified impurities are commonly limited to not more than 0.5 percent for any individual related substance and not more than 1.5 percent total related substances. Unspecified impurities are commonly controlled to limits of 0.10 percent or lower depending on regulatory requirements. Typical ancillary quality limits include residual solvents within ICH Q3C class limits, heavy metals below pharmacopoeial thresholds (for example less than 20 parts per million), and water content controlled by Karl Fischer titration to a low percentage as defined in finished product monographs. Specific impurity profiles can include desalkylated derivatives, N-oxide species and hydrolysis products; exact identification and limits are set by the manufacturer and accepted regulatory monograph.
Oxolamine is used as a symptomatic antitussive to suppress cough associated with upper respiratory tract irritation and inflammation; it is often included in oral formulations such as tablets and syrups and may be combined with expectorants or other symptomatic agents for relief of cough.
Oxolamine citrate works mainly by reducing inflammation and lowering the sensitivity of sensory nerve endings in the respiratory mucosa, which reduces the afferent signaling that triggers the cough reflex; the citrate salt form improves aqueous solubility and supports predictable oral absorption, while systemic metabolism and elimination follow standard small-molecule pathways determined during formulation and regulatory testing.
